AEON Law: Patent Poetry: Can cannabis patents be enforced?

Can pot patents be
Enforced in federal courts?
It’s up in the air…

Adam Philipp


Under the illegality doctrine, courts won’t enforce contracts or claims based on illegal acts.

As Bloomberg Law notes,

The illegality doctrine comes from the Highwayman’s case, a 1725 case in which an English court refused to entertain a lawsuit by one highway robber against his partner-in-crime who allegedly cheated the plaintiff out of his share of stolen earnings.

Some have argued that this doctrine should (or shouldn’t) apply to the enforcement of patents related to cannabis.

As the Marijuana Policy Project notes,

Except in very rare circumstances, at the federal level, marijuana and marijuana products are illegal and subject to criminal law enforcement through the Drug Enforcement Agency, or DEA.

However, 21 states, along with Guam and Washington, DC, have acted to legalize recreational marijuana. Thirty-seven states have legalized the medical use of marijuana.

Legal marijuana sales are thriving and in 2021 the states that legalized marijuana for personal consumption generated $3.7 billion in annual tax revenue related to the industry.

The number of cannabis-related patent and trademark filings has skyrocketed in the years since states started legalizing marijuana. The US Patent and Trademark Office (USPTO) refuses to grant trademarks for cannabis products that are illegal under federal law, but the USPTO doesn’t prohibit the filing of patents related to cannabis.

As with any business, intellectual property (IP) can be an important asset in the cannabis industry. However, can federal courts enforce federal patent rights that relate to a substance that’s still illegal under federal law?

In GENE POOL TECHNOLOGIES, INC. v. COASTAL HARVEST, LLC, Gene Pool is a company that focuses on cannabis and hemp extraction technologies. Coastal Harvest makes and sells products extracted from cannabis. Gene Pool sued Coastal in 2021 for allegedly infringing three of Gene Pool’s patents.

These patents don’t disclose or specifically address the use of marijuana products, and Gene Pool doesn’t actually use any of them in its business. Coastal accused Gene Pool of being a non-practicing entity (sometimes known as a “patent troll”), with a business model based on extorting license fees from alleged patent infringers.

Coastal moved to dismiss the case based on the doctrine of illegality, arguing that Gene Pool was trying to use the court to divide up revenues from illegal activity – just as in the Highwayman Case.

Gene Pool made several arguments in response:

  • The precedents cited by Coastal related to contract and bankruptcy law and weren’t relevant to a patent infringement dispute.
  • There was no connection between any illegal acts by Gene Pool and the patent claims.
  • Making cannabis companies immune from patent infringement claims would be against public policy, as inventors would have no incentive to file such patents.

The judge denied the motion to dismiss for illegality without a written opinion, stating only that it was for reasons stated on the record. The case is scheduled to go to trial in October 2023.

The Bloomberg Law article cited above suggests that the illegality doctrine should not apply to cannabis patents, for the following reasons:

First, the illegality doctrine does not apply to cannabis patents, since the rights granted under these patents are not the fruit of a crime.

It also is not illegal to get U.S. patents for research and development on cannabis done in Canada or overseas, e.g., the U.S. patents issued to GW Pharmaceuticals covering its Epidiolex drug. Cannabis patents can, and in many cases do, result from perfectly legal conduct that cannot be equated to a private division of loot between two crooks.

A patent confers the “right to exclude others” from making or using the invention, it does not grant the patent owner a right to make or sell the invention. The power to prevent others from making, using, or selling a cannabis-related invention does not violate federal drug law. Therefore, there is no good reason to apply the illegality doctrine to prevent enforcement of these patents against alleged infringers in a federal court.

Just like the haiku above, we like to keep our posts short and sweet. Hopefully, you found this bite-sized information helpful.


Top 200 Cannabis Lawyers

We Support

Cannabis Law Journal – Contributing Authors

Editor – Sean Hocking

Author Bios

Matt Maurer – Minden Gross
Jeff Hergot – Wildboer Dellelce LLP

Costa Rica
Tim Morales – The Cannabis Industry Association Costa Rica

Elvin Rodríguez Fabilena


Julie Godard
Carl L Rowley -Thompson Coburn LLP

Jerry Chesler – Chesler Consulting

Ian Stewart – Wilson Elser Moskowitz Edelman & Dicker LLP
Otis Felder – Wilson Elser Moskowitz Edelman & Dicker LLP
Lance Rogers – Greenspoon Marder – San Diego
Jessica McElfresh -McElfresh Law – San Diego
Tracy Gallegos – Partner – Fox Rothschild

Adam Detsky – Knight Nicastro
Dave Rodman – Dave Rodman Law Group
Peter Fendel – CMR Real Estate Network
Nate Reed – CMR Real Estate Network

Matthew Ginder – Greenspoon Marder
David C. Kotler – Cohen Kotler

William Bogot – Fox Rothschild

Valerio Romano, Attorney – VGR Law Firm, PC

Neal Gidvani – Snr Assoc: Greenspoon Marder
Phillip Silvestri – Snr Assoc: Greenspoon Marder

Tracy Gallegos – Associate Fox Rothschild

New Jersey

Matthew G. Miller – MG Miller Intellectual Property Law LLC
Daniel T. McKillop – Scarinci Hollenbeck, LLC

New York
Gregory J. Ryan, Esq. Tesser, Ryan & Rochman, LLP
Tim Nolen Tesser, Ryan & Rochman, LLP
Cadwalader, Wickersham & Taft LLP

Paul Loney & Kristie Cromwell – Loney Law Group
William Stewart – Half Baked Labs

Andrew B. Sacks – Managing Partner Sacks Weston Diamond
William Roark – Principal Hamburg, Rubin, Mullin, Maxwell & Lupin
Joshua Horn – Partner Fox Rothschild

Washington DC
Teddy Eynon – Partner Fox Rothschild